<![CDATA[Phase 2 OPAL Study to Test Muscle-Targeting Therapy Apitegromab in Infants With SMA]]>
Post Content: Source: Neurology Read More
<![CDATA[NeuroVoices: Claire Henchcliffe, MD, DPhil, on Rebranding the AUPN and Takeaways From the 2025 Meeting]]>
Post Content: Source: Neurology Read More
<![CDATA[Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy]]>
Post Content: Source: Neurology Read More
<![CDATA[Reinforce Ocrelizumab’s Role Across the Full Spectrum of More Advanced Progressive MS: Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath]]>
<![CDATA[FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology]]>
What APA Is Doing for You: Update on Clozapine REMS
In November 2021, the Food and Drug Administration (FDA) instituted a new Clozapine Risk Evaluation and Mitigation Strategy (REMS) to…
Read More
